Patent · US Active

Anti-CEA antibodies

US9206260B2 · kind B2 · utility

17Cited by

18References

13Claims

0Family size

Assignee

Roche Glycart AG · CH

Inventors

Thomas Hofer · Zürich, CH
Ralf Hosse · Baar, CH
Ekkehard Moessner · Kreuzlingen, CH
Pablo Umana · Wollerau, CH

Key dates

Filing date	Dec 20, 2013
Grant date	Dec 8, 2015
Priority date	—
Expiry date	Dec 20, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.